Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer

Table 4

Prediction of potential small molecular components based on the risk scores.

Rank	CMap name	Mean		Enrichment		Specificity	Percent nonnull
1	Lomustine	-0.804	4	-0.949	<0.0001	0	100
2	Oxybenzone	-0.454	4	-0.851	0.00093	0.0141	75
3	Trifluridine	0.291	4	0.819	0.00187	0.0421	50
4	Diethylstilbestrol	-0.493	6	-0.693	0.00209	0.0082	66
5	Prestwick-642	-0.336	4	-0.814	0.00223	0.0276	50
6	Chlorhexidine	-0.514	5	-0.71	0.00445	0.015	80
7	Indoprofen	-0.351	4	-0.765	0.00627	0.0333	50
8	Prestwick-857	-0.366	4	-0.762	0.00656	0.0127	50
9	Bromperidol	0.463	3	0.838	0.00831	0	66
10	Chenodeoxycholic acid	-0.381	4	-0.712	0.014	0.0923	50
11	STOCK1N-35874	-0.566	2	-0.915	0.01467	0.0331	100
12	Perhexiline	0.487	4	0.693	0.01862	0.1088	75
13	Pseudopelletierine	0.365	4	0.69	0.01908	0.0184	50
14	Hydrochlorothiazide	-0.446	5	-0.622	0.02005	0.0229	60
15	PHA-00767505E	-0.404	4	-0.687	0.02071	0.0127	75
16	Mometasone	-0.484	4	-0.68	0.02312	0.0342	75
17	Ciclopirox	0.39	4	0.679	0.02316	0.1594	75
18	0173570-0000	0.425	6	0.569	0.02384	0.1429	66
19	Eticlopride	-0.348	4	-0.676	0.02463	0.0758	50
20	Puromycin	0.441	4	0.663	0.02906	0.3258	75
21	Calcium pantothenate	0.379	4	0.662	0.02962	0.0413	50
22	Pimozide	0.426	4	0.659	0.03093	0.1457	75
23	Clopamide	-0.46	4	-0.657	0.03191	0.0284	75
24	Flumequine	0.476	4	0.647	0.03686	0.0567	75
25	Harpagoside	-0.178	4	-0.642	0.03945	0.0764	50
26	5194442	0.231	4	0.632	0.04559	0.0903	75